Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2022

View Archived Issues

Adenosine A2B receptor targeting protects against acetaminophen-induced hepatotoxicity

New STING agonists identified at The Scripps Research Institute

Orexia Therapeutics discovers orexin OX2 receptor agonists

The University of Southern California patents Huntingtin aggregation inhibitors

New STAT5 inhibitors synthesized at Janpix

New NLRP3 inflammasome inhibitors identified at NodThera

ANDY mouse mimics age-dependent NAD decline and its metabolic impact

Centrin-knockout L. mexicana show immunization promise for New World cutaneous leishmaniasis

AC-0027136 improves memory impairment and mitochondrial function

VYN-201 demonstrates promise in anti-collagen antibody-induced mouse model of RA

SBT-272 shows behavioral and metabolic improvements in mouse model of Huntington's disease

Eloxx expands ELX-02 development program to include Alport syndrome

New cathepsin L inhibitors for the treatment of HCC

Deleting protein switches macrophages to reduced-fat diet

Zelluna collaborates with Etcembly and Nextera to optimize pipeline TCRs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...